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Abstract
Lentiviral vector mobilization following HIV-1 infection of vector-transduced cells poses biosafety 
risks to vector-treated patients and their communities. The self-inactivating (SIN) vector design 
has reduced, however, not abolished mobilization of integrated vector genomes. Furthermore, an 
earlier study demonstrated the ability of the major product of reverse transcription, a circular SIN 
HIV-1 vector comprising a single-LTR to support production of high vector titers. Here, we 
demonstrate that configuring the internal vector expression cassette in opposite orientation to the 
LTRs abolishes mobilization of SIN vectors. This additional SIN mechanism is in part premised 
on induction of host PKR response to double-stranded RNAs comprised of mRNAs transcribed 
from cryptic transcription initiation sites around 3’SIN-LTR’s and the vector internal promoter. As 
anticipated, PKR response following transfection of opposite orientation vectors, negatively affects 
their titers. Importantly, shRNA-mediated knockdown of PKR rendered titers of SIN HIV-1 
vectors comprising opposite orientation expression cassettes comparable to titers of conventional 
SIN vectors. High titer vectors carrying an expression cassette in opposite orientation to the LTRs 
efficiently delivered and maintained high levels of transgene expression in mouse livers. This 
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study establishes opposite orientation expression cassettes as an additional PKR-dependent SIN 
mechanism that abolishes vector mobilization from integrated and episomal SIN lentiviral vectors.
Introduction
Recent successes of lentiviral vector-based gene replacement1, 2 and immunotherapy3, 4 at 
transmuting the pathologic course of human genetic and malignant proliferative diseases 
opened a new age in medicine. However, potential vector mobilization following infection of 
vector-transduced cells with HIV-1 poses biosafety risks to vector-treated patients and their 
communities. The development of self-inactivating (SIN) vectors significantly reduced, yet 
not abolished mobilization of integrated SIN vector genomes. The concept of SIN retroviral 
vectors is premised on deletion of the parental HIV-1 promoter and enhancer sequences from 
the 3’U3 in the vector cassette. The deleted 3’U3 is copied in the process of reverse-
transcription to the 5’U3. Consequently, reverse-transcribed SIN vector genomes devoid of 
the parental enhancer promoter sequences should not support transcription of vector length 
mRNA. Although the first SIN vectors were developed by Yu et al as a means to enhance 
biosafety of ɣ-retroviral vectors 5 Shinya et al were the first to describe a SIN lentiviral 
vector.6 The first efficient SIN lentiviral vector system was developed and successfully 
employed by Miyoshi et al to transduce rat retina and brain tissues.7 However, later studies 
reported on residual SIN vector mobilization, due to initiation of aberrant transcription of 
vector length mRNA from SIN LTRs.8–10 This phenomenon was attributed to HIV-1 
sequences within the vector’s packaging signal 9 and to host chromatin structures and 
regulatory elements in proximity to integrated vector genomes.8 The majority of lentiviral 
vector genomes shortly after transduction comprises episomal linear and circular (containing 
either one or two LTRs) DNAs. However, the ability of episomal lentiviral genomes to 
support vector mobilization has not been studied. Furthermore, in an earlier study, Ma et al 
employed a circular SIN vector genome comprising a single LTR to produce high titer 
lentiviral vectors.11 Concerned by these data, we sought to abolish residual vector 
mobilization from integrated and episomal vector genomes by incorporating an additional 
level of safety to the currently used SIN lentiviral vector system. We reasoned that any 
additional biosafety measure to eliminate vector mobilization should be mechanistically 
independent and thus, synergistic to the current SIN vector design in preventing vector 
mobilization. We theorized that configuring the vector internal expression cassette in 
opposite orientation (ECOO) to the SIN LTRs would minimize aberrant transcription from 
SIN LTRs (mediated by either the vector internal promoter11, parental HIV-1 sequences,9 or 
host regulatory elements8) and induce host Protein kinase-R (PKR) response to double 
stranded RNAs comprising LTR- and internal promoter-initiated transcripts. Indeed, here, 
we demonstrate dramatic reduction of vector mobilization from integrated and episomal 
lentiviral vector genomes comprising ECOO to the LTRs. Similar to earlier publications, 
lentiviral vectors carrying ECOO to the LTRs exhibited low titers12, 13. However, stable 
shRNA-mediated knockdown of PKR in vector producing cells rendered titers of the novel 
mobilization resistant vectors comparable to titers of their counterpart vectors, comprising 
expression cassettes in the same orientation to the LTRs. High titer mobilization resistant 
SIN vectors efficiently delivered and maintained firefly luciferase expression in mouse 
livers. Furthermore, we report here on efficient production of a lentiviral vector carrying an 
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ECOO encoding a modified human β-globin protein under the regulation of the β-globin 
locus control region13. This study elucidates the mechanism of SIN vector mobilization, and 
establishes a highly efficient methodology of generating mobilization-resistant lentiviral 
vectors comprising expression cassettes in opposite orientation to the LTRs.
Methods and Materials
Cells
SODK014 and 293T cells were maintained in DMEM-High Glucose (Thermo Scientific, 
Waltham, MA) supplemented with 10% FBS (Atlantic biologicals, Miami, FL), 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 250 ng/ml amphotericin B (Corning Cellgro, 
Manassas, VA). The SODK1 cell line 14 and all its derivatives were cultured in the pre-
mentioned medium with the presence of 1 µg/ml Doxycycline (Dox) . HepG2 cells were 
cultured in MEM (Gibco, Gaithersburg, MD) medium with 10% FBS and antibiotics. 
shRNA’s targeting the hPKR and hβ-globin(HBB) genes in 293T cells were delivered by 
lentiviral vectors obtained from the TRC1 library. These include clones: TRCN0000196400 
(pKR sh1), TRCN0000197012 (PKR sh2) and TRCN000002909 (HBB). Vector transduced 
293T cells were selected with 1µg/ml puromycin (Invivogen, San Diego, CA) for two 
continuous weeks. PKR knockdown was confirmed by Western blot.
Plasmids
The lentiviral vector pTK485, pTK945, pTK979 and the packaging cassettes ΔNRF, 
pTK939 (Int-), VSV-G envelope, pMDL and the Rev plasmids, were described earlier 15–18. 
The Tat plasmid was a kind gift from Dr. Thomas Hope. All other lentiviral vector plasmids 
were generated by standard restriction enzyme digestion and ligation (New England Biolabs, 
Ipswich, MA). To simplify the cloning procedure, we synthesized a plasmid pTK1866 
containing BamHI-cPPT-opposite orientated BGH - multiple cloning site (MCS) - WPRE- 
LTR-PmeI. BGH was flanked by BstZ17I, WPRE was flanked by ClaI to make future 
modification feasible. The expression cassette of CMV-GFP in pTK945 was generated by 
EcoRI/SpeI, blunted with DNA Polymerase Klenow Fragment, and inserted into HpaI 
located within MCS of pTK1866 with opposite orientation. The WPRE region was removed 
by ClaI digestion and re-ligation. The BGH in the aforementioned plasmid was removed by 
BstZ17I, and exchanged with SV40 Polyadenylation from pCI-neo by SmaI/FspI double 
digestion. The region (cPPT- SV40 op-GFP-CMV -WPRE-LTR) was digested by BamHI/ 
PmeI to substitute their counterparts in pTK945. To generate pTK1940 (GenBank accession 
MH297436), a ClaI fragment comprising the WPRE (nt 2908-3496 in pTK1940 and 
pTK1956) sequence was inserted in opposite orientation to the LTRs into a BsiWI site 
downstream to the SV40 polyA. pTK 1956 (GenBank accession MH297437) was created by 
replacing CMV-GFP expression cassette (XhoI/AscI) with hAAT-luciferase (AfeI/XhoI) 
from pTK979. All the unmatched overhung enzymatic digestion sites were blunted by DNA 
Polymerase I, Klenow Fragment, before ligation. All plasmids were confirmed by 
sequencing and restriction enzyme digestion.
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Viral vector production and concentration
Lentiviral vector production via 3 plasmids transient transfection was described earlier. 16 
For animal studies, viral vectors were concentrated by sucrose ultracentrifugation as 
described earlier. 19 Absence of replication competent retroviruses (RCR’s) was verified by 
three independent safety assays (GFP rescue assay, Tat transfer assay and Gag transfer 
assay) as described earlier. 14
Viral vector titration
Titers of vector transducing units (TU/ml) were determined by scoring GFP positive cell 
number under fluoresce microscope following serial dilutions on 293T cells. Titers of 
physical vector particles were determined by p24gag ELISA.20 Vector copy number (VCN) 
was determined by multiplex PCR using the ABI7300 realtime PCR system. NotI794 
primer/prober set (F5’- taagaccaccgcacagca-3’; R5’- cacttctccaattgtccctca-3’; Roche 
Universal Probe Library (UPL) #25, 4686993001, Indianapolis, IN) was used for vector 
detection, and paired with human RNaseP primer/probe set (Thermo Scientific 4316844,) or 
mouse GAPDH (Roche 05190525001) as a reference gene.21
Western blot analysis
Naïve, PKR knocked down and β-Globin knocked down 293T cells were lysed in RIPA 
buffer. Protein samples were separated on 10% SDS–PAGE denaturing gels. Blots were 
detected with PKR antibody (1:1000, Cell signaling Technology, Cat# 3072S, Danvers, MA) 
or β-actin antibody (1: 1000,Santa Cruz, Cat# sc-1616, Dallas, TX) followed by a polyclonal 
goat anti-rabbit secondary Ab labeled with horseradish peroxidase (1:10,000; Pierce, Grand 
Island, NY ) treated with ECL (GE Health Amersham, Pittsburgh, PA), and imaged by the 
ChemiDoc MP Imaging System (BioRad, Hercules, CA).
FACS analysis
Target cells were harvested at 48 hours post-transduction with GFP expressing vectors. 
Harvested cells were washed with PBS, fixed with 2% paraformaldehyde for 15 minutes, 
and re-suspended in MACS buffer (2mM EDTA and 1%BSA in PBS). Fluorescence-
activated cell sorter (FACS) analysis was performed with CyAn ADP (Becton–Dickinson). 
Percentage of GFP positive cell and mean fluorescence intensity (MFI) were analyzed with 
the FlowJo9.3.2 (Flowjo LLC, Ashland, OR) software.
Mobilization of integration deficient lentiviral vectors (IDLV) from the inducible packaging 
cell line SODK1
The inducible packaging cell line SODK114 was employed to evaluate IDLV mobilization. 
To induce vector production, SODk1 cells were washed with PBS (X3), and passaged onto 
poly-lysine (Sigma, St Loius, MO) pre-coated plates and cultured in doxycycline (Dox)-free 
media. At 5 days post-Dox withdrawal, 15 million cells were seeded onto 10cm plate for 
IDLV mobilization analysis. On day 6-post Dox withdrawal, 2×108 TU of IDLV were 
employed on the induced SODK1 cells in the presence of 5mM sodium butyrate. At twelve 
hours post-transduction, cells were washed and cultured with Dox-free fresh media 
containing 5mM sodium butyrate. Vector particles containing media were collected at 72 
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hours after addition of sodium butyrate. IDLV transduced SODK1 cells cultured in the 
presence of Dox (1µg/µl) and sodium butyrate (5mM) media served as controls. Mobilized 
vector particles were employed on 2-million naïve 293T target cells. To eliminate carrying 
over of non-mobilized IDLVs, titers of mobilized ICLVs (generated by the induced 
packaging cells) were determined after 5 passages of the above target cells in culture. 
Percent of GFP-positive cells and the number target cells at the time of transduction were 
used to calculate vector titers.
Mobilization of integration competent lentiviral vector (ICLV) from the inducible packaging 
cell line SODK1
SODK1 cells were transduced with ICLVs particles at an m.o.i. of 10. To dilute out episomal 
vector genomes, transduced SODk1 cells were passaged in culture (X5). To initiate vector 
production, transduced SODK1 cells were washed with PBS (X3), and passaged onto poly-
lysine coated plates in Dox-free media. At 5 days post-Dox withdrawal, 15 million cells 
were seeded onto 10cm plate. Sodium butyrate (5mM) was added to culture media at day 6 
post-Dox withdrawal. Vectors particles containing media were collected at 72 hours after 
addition of sodium butyrate. IDLV transduced SODK1 cells cultured in the presence of Dox 
(1µg/µl) and sodium butyrate (5mM) media served as controls. Titers (TU/ml) of mobilized 
vectors were determined by scoring GFP expression following serial dilutions on 293T cells.
Luciferase assay
Vector transduced HepG2 cells were lysed at 72 hr post-transduction and quantified with 
1420 Multilabel Counter Victor 3 (PerkinElmer Waltham, MA) following manufacturers 
instruction of Luciferase Assay system (Promega Madison, WI). Relative Light Units (RLU) 
were further normalized with protein concentration and viral copy number (VCN per cell). 
Protein concentration was determined by the Braford method.
Animal studies
All animal cares and procedures were in accordance with the Guide for the Care and Use of 
Laboratory Animals and received prior approval by the UNC Animal Care and Usage 
Committee (Animal protocol 15-123.0). C57BL/6J female mice at age 5~6 week old were 
obtained from Jackson Lab. One week after animal arrival, 25 µg p24gag lentiviral vectors 
were administrated into each mouse via intraperitoneal injection. In vivo expression of 
vector-delivered firefly luciferase in live animals was determined at weeks 2, 4, 6 and 8 
using IVIS Lumina optical system (PerkinElmer, Waltham, MA), as described previously. 21 
Shortly, mice were injected with 250µl luciferin substrate (25mg/ml, Regis Technology, 
Grove, IL) via I.P. After 10 minutes incubation, mice were imaged for 5 minutes with IVIS 
imagine system.
Statistical analysis
Student’s T test in Excel software was used to determine the significance of in vitro assay of 
vector pTK 979 and pTK 1956.
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Results
A circular SIN single-LTR vector cassette supports Tat independent production of high 
titer lentiviral vectors
Mobilization of HIV-1 based vectors following infection of vector-transduced cells with HIV 
and consequential spread of vector particles in vector-treated patients and their communities 
are major biosafety concerns. Using cell lines comprising integrated SIN vector genomes, 
several groups demonstrated significant reduction yet not complete elimination of lentiviral 
vector mobilization.8, 9 Although circular single-LTR vector genomes are a major product of 
lentiviral vector reverse transcription15, 22–24, their ability to mobilize packageable vector 
genomes has not been evaluated. Furthermore, in an earlier study, Ma et al., demonstrated 
that a DNA construct encoding a circular SIN single-LTR vector supported production of 
high vector titer 11. Since the precursor of the aforementioned shuttle SIN vector described 
by Ma et al., was isolated from lentiviral vector-transduced cells, we further studied the 
mechanism of SIN vector mobilization. Specifically, we characterized the role of HIV-1 Tat 
protein in mobilization of circular SIN single-LTR genomes pTK485 (Figure 1A and 
supplement figure 1), which are naturally generated in vector-transduced cells15, 22–24. To 
this end, vTK485 particles were produced by a transient four-plasmid transfection 
procedure, either in the presence or absence of the HIV-1 Tat protein. As shown in Figure 
1B, production of high titer (3-4E+6 IU/ml) SIN vectors from a SIN single-LTR expression 
cassette (pTK485) was Tat-independent. These findings are in line with an earlier report by 
Poon et al.25 Vector mobilization from integrated SIN vector genomes was attributed to 
aberrant transcription initiation induced by either enhancer sequences located in the vector 
packaging signal or to host sequences in proximity to the vector integration site 8, 9. 
However, the high titers of SIN vectors generated from pTK485 indicated that a different or 
additional mechanism contributes to the highly efficient Tat-independent vector production 
from circular SIN vector genomes. Importantly, the process of vector circularization, locates 
the internal promoter upstream to the SIN LTR. Thus, we hypothesize that transcriptional 
activity induced by the internal promoter is the major contributor to episomal SIN vector 
mobilization. Furthermore, we theorized that positioning the internal expression cassette in 
opposite orientation to the LTR’s would significantly minimize internal promoter mediated 
mobilization of circularized episomal vectors.
Internal expression cassettes in opposite orientation to the LTR’s reduce production of 
lentiviral vector particles and vector titers
To reduce the likelihood of lentiviral vector mobilization, an internal expression cassette 
comprising the bovine growth hormone (BGH) polyadenylation (poly-A) site, a CMV 
promoter, and the green fluorescence protein (GFP) reporter gene was positioned in an 
opposite orientation to the SIN vector LTR’s (pTK1906 in Figure 2A). Production efficiency 
of pTK1906 by transient three-plasmid transfection was compared to production of its 
conventional counterpart vector (pTK945). As shown in figure 2B-C, positioning an internal 
expression cassette in opposite orientation to the LTRs dramatically reduced transducing- 
and physical- vector titers. Furthermore, the reduction in concentration of vector particles in 
culture media (as determined by p24gag ELISA) suggested that the opposite orientation 
expression cassette in the vector construct probably induced a host PKR response that 
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effectively inhibited synthesis of viral structural proteins encoded by the co-transfected 
packaging cassettes.
PKR deficient packaging cells support efficient production of ECOO containing lentiviral 
vectors
To study the effects of the host PKR response on titers of ECOO comprising vectors, U6-
shRNA expression cassettes carried by lentiviral vectors were employed to effectively knock 
down PKR expression in 293T cells (Figure 2D). Conventional and ECOO-comprising 
vectors were generated in either naïve or PKR deficient 293T cells. As shown in figure 2B-
C, PKR knockdown in vector producing cells resulted in a ten-fold increase in titers of 
ECOO-comprising vectors, with minimal effect on titers of conventional vectors. Next, we 
sought to delineate the mechanisms that induce PKR response following transfection of 
ECOO comprising vectors.
The origin and position of poly-A sites in the vector cassette affect lentiviral vector titers
An internal poly-A site is required to facilitate efficient transgene expression from vectors 
comprising ECOO’s. Hence, we sought to characterize the effects of poly-A sites positioned 
upstream and in opposite orientation to conventional internal expression cassettes (in same 
orientation to the LTRs) on vector titers (Figure 3A). To this end, SIN vectors comprising 
either internal BGH (pTK1588) or SV40 (pTK1595) poly-A sites were generated in either 
naïve or PKR deficient 293T cells. Vector titers were determined and compared with titers of 
their conventional counterpart vector (pTK945). Unexpectedly, titer analysis (Figure 3B) 
indicated that the origin of the internal poly-A site had a major effect on vector titers. 
Specifically, regardless of PKR expression in vector producing cells, titers of SIN vectors 
comprising an internal SV40 poly-A site (pTK1595) were comparable to titers of their 
parental vector (pTK945) lacking an internal poly-A site. Per contra, when generated in 
naïve 293T cells, titers of a vector comprising an internal BGH poly-A site (pTK1588) were 
more than a 100-fold lower than titers of either control vectors or same vectors generated in 
PKR deficient cells. Since none of the above vectors contains an ECOO, we theorized that 
transcription through the parental LTR poly-A produced a BGH poly-A sequence located 
downstream to the 3’LTR. Consequently, the transcribed full-length vector mRNA’s 
comprised two complementary BGH poly-A sites, which generated an intra-molecular 
double stranded RNA structure and induced a host PKR response that negatively affected 
vector titers. To test the above notion, we developed two SIN vectors lacking the 
downstream BGH poly-A site (Figure 3A). The novel two vectors, either, comprising or 
lacking the internal BGH poly-A site (pTK1850 and pTK1848, respectively) were generated 
in either naïve or PKR deficient cells. As shown in figures 3C-D, both vectors (pTK1850 
and pTK1848) exhibited comparable titers, which were only marginally lower than the titers 
of a conventional SIN vector (pTK945) containing a BGH poly-A site downstream to the 
3’LTR. These findings suggested that in the absence of a functional ECOO the mere 
presence of an internal poly-A site induces only a minor reduction in vector titers.
Transcription from ECOO reduces titers of SIN lentiviral vectors
Next, we sought to directly determine the effects of transcription from the ECOO at the time 
of vector production on vector titers. To this end, expression cassettes comprising an 
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inducible tetracycline promoter and either a BGH or SV40 poly-A site were incorporated in 
opposite orientation to SIN vectors (Figure 3A: pTK1885, pTK1927 and pTK1936. 
pTK1937, respectively). Furthermore, to evaluate the combined effect of vector design and 
ECOO transcription on vector titers, a BGH poly-A site was incorporated downstream of the 
3’LTR and compared to its unincorporated counterpart (Figure 3A: pTK1927, pTK1937 and 
pTK1885, pTK1936, respectively). Vector particles were generated by transient transfection 
in naïve and PKR deficient 293T cells either in the presence or absence of a tetracycline 
regulated trans activator (tTA). Vector titers were determined by scoring GFP expression 
following serial dilutions on 293- SODk0 cells, which constitutively express tTA.14 As 
shown in figures 3D-E, transcription from ECOO at the time of vector production (in the 
presence of tTA) significantly reduced vector titers generated in naïve 293T cells. The 
presence of two oppositely oriented BGH poly-A sites in pTK1927 further reduced its 
physical and transducing titers when generated in naïve 293T cells (Figure 3D-E). Per 
contra, transcription from ECOO and the presence of two BGH poly-sites in the vector 
cassettes had minimal effect on vector titers generated in PKR deficient 293T cells 
compared to the titers of a conventional SIN vector (pTK945). Note that transducing titers of 
vectors containing an internal SV40 poly-A site and a BGH poly-A site downstream to the 
3’LTR (pTK1937) were higher than the titers of their counterpart vectors (pTK1936) that 
lack a BGH poly-A site downstream to the 3’LTR (Figure 3D). These data suggest that 
transcription from ECOO negatively affects vector titers generated in naïve 293T cells. 
Furthermore, the presence of a BGH poly-A site downstream to the 3’ LTR increases titers 
of conventional vectors, however, the presence of both an internal and an external 
(downstream to the 3’LTR) BGH poly-A sites significantly reduces titers of ECOO-
comprising vectors.
Optimization of vector design to maximize titers of ECOO-comprising SIN vectors
To maximize titers of SIN vectors comprising ECOO, a series of vectors were developed to 
identify the optimal combination of poly-A sites within vector expression cassettes. (Figure 
4A). Specifically, expression cassettes comprising either BGH (pTK1886 and pTK1906) or 
SV40 poly-A sites (pTK1907, 1909, 1908 and 1918) were cloned in opposite orientation to 
the LTR’s in vector constructs either containing or lacking a BGH poly-A site downstream 
to the 3’LTR. Note that the SV40 poly-A site was cloned either in the same (pTK1908 and 
pTK1918) or opposite (pTK1907 and pTK1909) orientation to the LTR’s. Vectors particles 
were generated in naïve and PKR deficient 293T cells. Concentration of physical vector 
particles and transducing vector titers were determined by p24gag ELISA and GFP 
expression scoring following serial dilutions on 293T cells, respectively. Levels of transgene 
expression in vector-transduced 293T cells were analyzed by FACScan analysis 
(supplemental figure 2). As shown in figures 4B-C, when generated in PKR deficient cells, 
the titers of pTK1909, a vector comprising an internal SV40 poly-A in opposite orientation 
to the LTRs and a BGH poly-A site downstream to the 3’LTR were comparable to the titers 
of a conventional SIN vector (pTK945), and more than 10-fold higher than the titers of the 
other ECOO vectors. These data suggest that in the absence of intra-molecular double 
stranded RNA structures (generated by two complementary BGH poly-A sequences), 
efficient shRNA-mediated knockdown of PKR facilitates production of high titer ECOO 
comprising vectors. The presence of a BGH poly-A site downstream to the 3’LTR further 
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increases titers of vectors comprising an internal SV40 poly-A. Interestingly, internal SV40 
poly-A sites positioned in opposite orientation to the internal CMV promoter (Figure 4A, 
pTK1908 and pTK1918) did not reduce transgene expression levels from ECOO (Figure 
4D). Furthermore, transgene expression levels from all ECOO vectors were significantly 
lower than the level of expression from the conventional vector control, pTK945 (Figure 4D) 
indicating that addition of the woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) to the internal expression cassette could improve the efficiency of ECOO 
comprising vectors.
Incorporation of the WPRE to ECOO’s increases levels of transgene expression
To enhance transgene expression from ECOO comprising vectors, a DNA sequence 
encoding the WPRE was positioned between the GFP reporter gene and the internal poly-A 
site (Figure 5A, pTK1940, GenBank accession MH297436). To address the concern that the 
lack of a WPRE sequence upstream to the 3’LTR would reduce vector titers, an additional 
WPRE sequence was incorporated between the 3’LTR and the BGH poly-A site (Figure 5A, 
pTK1954). Vector particles were generated either in naïve or PKR deficient 293T cells. 
Concentration of physical vector particles and vector titers were determined by 
p24gagELISA and by scoring GFP expression following serial dilutions on 293T cells 
(Figures 5B-C). Transgene (GFP) expression levels were determined by FACScan analysis. 
As shown in figures 5A and D, positioning a WPRE sequence between the transgene of 
interest (GFP) and the internal SV40 poly-A rendered transgene expression from ECOO 
(pTK1940 and pTK1954) comparable to the levels of expression obtained from a 
conventional vector control (pTK945). Interestingly, addition of a WPRE sequence between 
the 3’LTR and the BGH poly-A site (pTK1954) significantly reduced production of physical 
vector particles and vector titers generated in naïve 293T and to a lesser extent in PKR 
deficient cell lines cells (Figures 5C-D). Note that positioning a single WPRE sequence 
between the transgene of interest and the internal SV40 poly-A site (pTK1940) had no effect 
on production of physical vector particles nor on vector titers generated in PKR deficient 
cell lines.
Superior transgene expression from integration deficient ECOO comprising lentiviral 
vectors
Intrigued by recent successful integration deficient lentiviral vectors (IDLV)-mediated gene 
delivery for vaccination and cancer immunotherapy in preclinical studies and human clinical 
trials, respectively4, 26, we sought to characterize the efficiency of transgene expression from 
integrase deficient ECOO comprising vectors. To this end, conventional and ECOO 
comprising vectors (pTK945 and pTK1940, respectively) were packaged into integrase-
deficient vector particles and employed on 293T cells. Levels of transgene (GFP) expression 
were determined by FACScan analysis. As shown in figure 5E, transgene expression levels 
from ECOO comprising IDLV (pTK1940) were significantly higher than the levels of 
expression obtained from its conventional IDLV counterpart (pTK945).
Efficient transgene expression from a liver-specific promoter in ECOO comprising vectors
Several earlier studies demonstrated efficient liver transduction by lentiviral vectors carrying 
reporter and clinically relevant cDNAs 15, 21, 27. Hence, we sought to test the ability of 
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ECOO comprising vectors to efficiently deliver and express a reporter gene under control of 
a liver specific promoter. To this end, an expression cassette comprising the liver specific 
promoter (hAAT), the firefly luciferase cDNA, the WPRE sequence and the SV40 poly-A 
was cloned in opposite orientation to the LTR’s (Figure 5F: pTK1956, GenBank accession 
MH297437). Vector particles of the above novel liver specific vector and its conventional 
counterpart (Figure 5F: pTK979) were generated by transient transfection14 and employed 
on the HepG2 cells. Levels of luciferase expression normalized to vector copy number were 
analyzed as described earlier. 21, 24 As shown in figure 5G, normalized expression levels 
were higher in HepG2 cells transduced with the ECOO comprising vectors than the 
normalized expression levels in similar cells transduced with a conventional vector.
Minimal mobilization of ECOO comprising vectors
To further characterize the suitability of ECOO comprising vectors for future clinical 
applications, we sought to compare their mobilization potential to that of conventional 
lentiviral vectors. ECOO comprising vectors (pTK1940) and their conventional SIN 
(pTK945) and non-SIN (pTK1087) counterparts (Figures 3A, 5A and 6A) were packaged by 
transient transfection into vector particles comprising either functional or mutant integrase 
(D64E) protein. Thus, generating integration competent and integration defective lentiviral 
vectors (ICLV and IDLV respectively). 15, 24, 27, 28 To specifically evaluate mobilization of 
episomal forms of the above vectors, IDLVs were employed on the tetracycline regulated, 
HIV-1 vector packaging cell line SODk1 14 either prior (in the presence of doxycycline) or 
after inducing (in the absence of doxycycline) production of VSV-G- pseudotyped vector 
particles . Titers of mobilized integrating vectors in conditioned media were determined by 
scoring GFP expression following serial dilutions on 293T cells. To eliminate potential 
carryover of the parental IDLV particles, the transduced reporter 293T cells were passaged 5 
times prior to scoring GFP expression. As shown in figure 6B, titers of mobilized SIN IDLV 
(pTK945) were only mildly lower than the titers of mobilized non-SIN IDLV’s (pTK1087). 
These data suggest that vector mobilization from episomal vector genomes is independent of 
the parental HIV-1 promoter/enhancer sequences and is in line with the Tat independent 
production of a SIN single-LTR vector (Figure 1B). 11 Importantly, titers of mobilized 
episomal ECOO-comprising vectors (pTK1940) were more than fifty-fold lower. 
Mobilization efficiency of episomal SIN vector from a stable packaging cell line as 
described here was significantly higher than the level of mobilization of conventional 
integrated SIN vectors described earlier.8, 9 To characterize mobilization of integrated 
ECOO-comprising vectors, the above ICLVs (pTK1087, pTK945 and pTK1940) were 
employed on SODk1 cells. To dilute out episomal vector forms, transduced SODk1 cells 
were cultured in the presence of doxycycline for more than 2 weeks (5 passages) after which 
production of VSV-G-pseudotyped vector particles was induced by doxycycline withdrawal 
as described earlier 14, 29. Titers of integrating vector particles in conditioned media were 
determined by scoring GFP expression following serial dilutions on 293T cells. Vector copy 
number in SODk1 cells prior to doxycycline withdrawal was determined by qPCR. 30 As 
shown in figure 6C-D, titers of mobilized integrated conventional SIN vectors (pTK945) 
were several hundred fold lower than the titers of their non-SIN counterparts (pTK1087). 
These results are in line with the data presented earlier by Logan et al. and Hanawa et al. 8, 9 
Most importantly, titers of mobilized ECOO comprising vectors were at the limit of 
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detection (less than 10 TU/ml) and several hundred fold lower than the titers of mobilized 
conventional SIN vectors (pTK945). Furthermore, normalization of vector titers for vector 
copy number in SODk1 cells has not affected the observed differences in mobilization 
efficiency of conventional and ECOO-comprising vectors (Figure 6C). Intrigued by the low 
mobilization levels of ECOO-comprising SIN vectors (pTK1940), we sought to study the 
effects of positioning a lentiviral vector’s expression cassette in opposite orientation to the 
LTRs on mobilization of non-SIN vectors. To this end, a novel ECOO-comprising non-SIN 
vector pTK1976 was transduced on either naïve or PKR-deficient cells. In addition, 
conventional non-SIN and SIN vectors pTK1087 and pTK945 as well as the ECOO-
comprising SIN vector pTK1940 were employed on naïve 293T cells and VCN was 
determined by qPCR. To characterize the level of vector mobilization, the above vector-
transduced cells were transiently transfected with a VSV-G envelope and a lentiviral vector-
packaging cassette. Titers of mobilized vectors in conditioned media were determined by 
scoring GFP expression following serial dilutions on 293T cells. As expected and shown in 
figures 6E-F, conventional non-SIN vector (pTK1087) exhibits the highest mobilization 
titers (prior and after normalization to VCN in vector producer cells). However, the mere 
positioning of the internal vector expression cassette in opposite orientation to the LTRs 
reduced VCN-normalized mobilization titers of non-SIN vectors (pTK1976) from 293T 
cells by more than 500–fold. These mobilization titers were only 5-fold higher than the 
mobilization titers of conventional SIN vectors (pTK945). Interestingly, VCN-normalized 
mobilization titers of pTK1976 from PKR-deficient 293T cells were more than 4-fold higher 
than the titers generated by naïve 293T cells. These data suggest the reduction in 
mobilization-titers of non-SIN ECOO-comprising vectors (pTK1976) is mediated by PKR-
dependent and -independent mechanisms. Importantly, further analysis of vector 
mobilization-titers shows 96- and 18-fold reduction in vector mobilization titers following 
conversion of the parental LTR configuration in pTK1976 to a SIN one (similar to 
pTK1940-LTR) and after reverting the conventional orientation of the internal expression 
cassette in pTK945 (similar to pTK1940 vector design), respectively. Altogether, these 
findings indicate that three independent mechanisms (SIN vector design and the above two 
ECOO-related mechanisms) synergistically inhibit mobilization of ECOO-comprising 
integrated SIN vectors. Note that, under the above extreme conditions, mobilization of 
pTK1940 was not completely abolished. We speculate that some vector producing cells 
transcribe low levels of full length packagable mRNA, which do not elicit a robust PKR 
response. This facilitates production of low yet measurable levels of mobilized vector 
transducing units.
Superior hepatic gene delivery by ECOO comprising vectors
Minimal mobilization and efficient transgene expression render ECOO comprising vectors 
better suited to in vivo gene delivery applications than their conventional counterpart. Hence, 
we sought to evaluate the efficacy of ECOO-comprising vectors at hepatic gene delivery by 
direct comparison with their conventional counterparts. To this end, ECOO-comprising and 
conventional lentiviral vectors carrying the firefly luciferase under control of a liver specific 
(hAAT) promoter (Figure 5F: pTK1956 and pTK979, respectively) were packaged into 
VSV-G pseudotyped ICLVs. Concentrated vector particles were injected intraperitonealy to 
C57B6 mice (25µg p24gag/mouse). Luciferase expression in mouse livers was periodically 
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imaged and quantified by the IVIS Lumina imagine system. As shown in figures 7A-B, 
transgene expression levels in mouse livers transduced with ECOO comprising vectors 
(pTK1956) were more than 5 fold higher than the levels of hepatic luciferase expression 
from conventional vectors (pTK979). These data underscore the superiority of the recently 
developed ECOO comprising vector as a means of in vivo gene delivery vehicle.
Efficient production of ECOO comprising vectors for clinically relevant ex-vivo 
applications
To further characterize the efficacy of the PKR-deficient packaging system at generating 
ECOO comprising vectors, we sought to evaluate production of a lentiviral vector, which 
was specifically developed for hematopoietic stem cell gene therapy in sickle cell disease 
patients. Romero et al. described the novel ECOO comprising vector, CCL-β AS3-FB, 
earlier (Figure 7C). 13 It encodes the modified human β-globin protein HbAS3 31 and 
contains the parental β-globin gene regulatory elements including its promoter, introns, 
poly-A site and the mini-locus control region (LCR) with hypersensitive sites (HS) 2-4. To 
support long-term and stable transgene expression, a 77bp insulator was incorporated in the 
vector’s SIN 3’U3. Similar to other lentiviral vectors, which efficiently delivered β-globin 
expression cassettes, the novel CCL-β AS3-FB exhibited low titers. 13, 32, 33 We conjectured 
that producing the CCL-β AS3-FB vector in PKR deficient cells would increase its titers. To 
test this hypothesis, CCL-β AS3-FB vector and a conventional vector (Figure 3A: pTK945) 
were generated by transient transfection in either naïve or PKR deficient 293T cells. Vector 
titers and concentration of physical vector particles in condition media were determine by 
qPCR on vector transduced 293T cells and by p24gag ELISA. As shown in figure 7D-E, 
titers of CCL-β AS3-FB vector generated in PKR deficient 293T cells were merely 2-3 fold 
higher than vector titers generated in naïve 293T cells and yet comparable to titers of the 
control vector pTK945 (up to 2×108 TU/ml). Altogether, the data presented here describe an 
efficient methodology of producing ECOO comprising lentiviral vectors, which are safer and 
more efficient than their conventional counterparts and thus better suited for clinical trials.
Discussion
Following numerous preclinical studies, years of promises, expectations, and early setbacks,
34–37
 recent accumulating successes of gene therapy clinical trials opened a new era in 
modern medicine. Currently, viral vectors serve as the method of choice to deliver 
therapeutic genetic cargos in gene therapy clinical trials. Lentiviral and AAV-based vectors 
have been used as a means to cure cancer as well as hereditary and acquired human diseases, 
most of which were not effectively treatable by conventional medicine.1, 3, 38–41 US FDA 
approvals of lentiviral and AAV vectors-based gene therapy to treat hematopoietic and 
lymphoid malignancies and a hereditary retinal disease 42–44 formally established a novel 
class of medications. Similar to conventional medications, the scope of disease indications 
for gene therapy protocols is dictated by risk/benefit considerations. Findings of earlier ɣ-
retroviral and lentiviral vector-based preclinical studies and human clinical trials raised 
biosafety concerns regarding potential emergence of replication competent retroviruses 
(RCR) and integrating vector mediated insertional mutagenesis.34, 45–49. These biosafety 
concerns were significantly eased by a recent study summarizing biosafety test results of 
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cancer and HIV-1 gene therapy clinical trials employing lenti/retro viral vectors-modified T 
cells.50 Overall, in these studies, biosafety assays of vector preparations, modified T-cells 
and treated patients could not detect RCR and demonstrated a long-term decrease in the 
vector modified T-cells population to less than 1%. These findings are highly encouraging, 
and yet additional studies are needed to characterize biosafety of ɣ-retroviral and lentiviral 
vector-based gene delivery in different clinical settings, especially those involving stem cell 
transduction and in vivo gene delivery. Lack of clinical and experimental reports on the 
adverse effects associated with vector mobilization reduced attention of regulators and 
investigators to this potential biosafety risk. Vector mobilization is defined as the undesired 
packaging and transfer of vector genomes from target cells, where they are performing a 
therapeutic objective, to other cell populations either within the host or to the community. 
Theoretically, vector mobilization can mediate several adverse processes including 
insertional mutagenesis, alteration in vector biodistribution, emergence of novel RCR’s, and 
induction of immune response to transgene products. Vector mobilization requires 
transcription of full-length vector genomes in a cell that concomitantly produces all viral 
proteins (structural and non-structural) needed to assemble productive vector particles. 
Genetic information encoding the above viral proteins could be provided by several 
mechanisms including inadvertent transferring of all or parts of the packaging cassettes to 
target cells, infection of target cells with parental wild type viruses, expression of 
endogenous retroviral genomes, or by a combination of these mechanisms. Human 
endogenous retroviruses (HERV), which invaded the human genome via germ cell infection 
in the last 2-40 million years, make ~8% of the human genome.51 Various genetic and 
epigenetic inactivation mechanisms rendered HERV non-infectious. However, human cell 
lines and tissues produce HERV proteins and noninfectious viral particles.52–55 Furthermore, 
infectious HERV viruses have been successfully reconstituted from human genomes.56, 57 
The HERV-K envelope proteins, syncytin 1 and 2 are involved in human placenta formation 
and can pseudotype lentiviral vectors.52, 58 Thus, the receptors to syncytin-1 and −2 
envelope proteins, which are synthesized in various human tissues (including germ cells), 
can potentially broaden biodistribution of syncytin-pseudotyped vectors.59–62
In contrast to AAV vector based therapies 63–65, the relatively small number of individuals 
that currently are or anticipated to be infected with HIV-1 reduces the likelihood of lentiviral 
vector mobilization. However, the necessity to avoid vector mobilization even in the 
presence of all HIV-1 proteins was the impetus to the development of SIN vectors, in which 
deletions of U3 sequences comprising the parental viral enhancer promoter inhibit 
transcription of full-length vector mRNA.5, 7, 66 Further characterization of SIN vector 
mobilization demonstrated reduced yet not completely abolished mobilization from 
integrated vector genomes. Vector mobilization in these studies was consequent upon cryptic 
transcription initiation of full-length vector mRNA, which was controlled by different 
transcription regulatory elements within the vector and in the host genome (determined by 
vector integration sites).8, 9 The fact that most of the cryptic transcription initiation sites 
reported by Hanawa et al. were downstream to the 5’R and could not produce full length 
packagable vector mRNA was in line with the relatively low titers (up to ~4×103 TU/ml) of 
SIN vectors mobilized from integrated vector genomes.8 Per contra, we show here that titers 
of SIN vectors mobilized from episomal vector genomes (Figures 1B and6B) are not 
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significantly lower than the titers of their non-SIN counterparts. In theory, minimal if any 
host-genome effect on transcription of non-integrating vectors should render episomal SIN 
vector less mobilized than integrating vectors. However, vector circularization potentially 
positions various internal transcriptional regulatory elements upstream to the vector’s single 
or double LTR’s. We assert that this circularization event creates a new Tat independent 
promoter/enhancer constellation that renders the enhancer/promoter deletions of the SIN 
LTR ineffective at preventing transcription of full length vector mRNA. This notion is in line 
with an earlier study by Poon et al. showing Tat independent transcription from episomal 
HIV-1 genomes.67 The relatively high rate of vector mobilization from episomal vector 
genomes is in line with earlier studies describing significant differences in regulation of 
transgene expression from episomal and integrated lentiviral vector genomes.15, 28 Episomal 
lentiviral vectors comprise the majority of reverse transcription products 15, 22, 68 and thus 
serve as an efficient template for transcription of mobilizable, full-length mRNA’s. In 
dividing cells, episomal vector genomes lacking origin of replication are rapidly lost by 
dilution.68 Consequently, ex-vivo gene therapy protocols including gene delivery to stem 
cells and genetic engineering of T-cells carry lower risk of episomal vector mobilization.1, 40 
Per contra, episomal vector genomes are highly stable in non-dividing cells; thus, in vivo 
administration of SIN lentiviral vector should raise biosafety concerns regarding potential 
vector mobilization.4
The development of the IDLV system successfully addressed the risk of insertional 
mutagenesis by reducing integration of vector genomes to less than 1%.24, 69 However, the 
risk of SIN vector mobilization is probably more significant following in vivo administration 
of IDLVs, considering more than 99% of their reverse transcribed genomes are episomes. 
Recently, 3’PPT-deleted vectors have been developed as a means to minimize illegitimate, 
integrase-independent integration of IDLV’s.24 The newly developed vectors have been 
successfully employed in immunotherapy clinical trials.4 3’PPT-deleted vectors generate 
mainly single-LTR circles, which are less likely than linear double-stranded vector genomes 
to recombine with the host genome, but are predicted to efficiently support vector 
mobilization.
To address the above biosafety concerns, we demonstrate here that positioning internal 
lentiviral vectors’ expression cassettes in opposite orientation to the LTRs, practically 
abolishes SIN vector mobilization. Premised on the fundamental differences in 
transcriptional regulation of gene expression from episomal and integrated vector 
genomes15, 67, we speculate that ECOO-associated reduction in vector mobilization from 
episomal and integrated vector genomes is mediated by different mechanisms. The relatively 
high levels of transgene expression from ECOO comprising IDLVs suggests that the 
negative effect of ECOO on episomal vector mobilization is probably secondary to silencing 
of cryptic transcription initiation sites in episomal vector’s SIN LTR and is not mediated by 
the host PKR response. Interestingly, three independent mechanisms reduce mobilization of 
integrated vectors. These include PKR-dependent and independent mechanisms that reduce 
mobilization of integrated non-SIN ECOO-comprising vectors and the SIN-LTR 
configuration that reduces mobilization of all integrated retroviral vectors. Consequently, 
ECOO-comprising vectors demonstrate the lowest level of mobilization, which renders them 
most suitable for a biosafety level-0 (BSL-0, the community), in which patients carrying 
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large numbers of viral vectors genomes can potentially mobilize viral vectors and their 
derivatives to the community. Several research groups successfully employed ECOO-
comprising vectors in hematopoietic stem cells (HSC)-based gene replacement therapy for 
different hemoglobinopathies.13, 31–33, 46, 70–73 To maintain long-term therapeutic level of 
transgene expression, most of the disease-tailored vectors carried human globin expression 
cassettes comprising transcriptional and post-transcriptional regulatory elements of the 
human β-globin gene including its’ promoter, mini-LCR, introns and poly-A site. However, 
difficulties in generating high vector titers limit the usage of these efficacious vectors in 
clinical trials.13, 32, 33 It is likely that the relatively large genetic payload of the above 
vectors negatively affect their titers. Since the parental globin promoter is not active in 293T 
cells, we observed merely a mild increase of ~2 fold in titers of the CCL-β AS3-FB vector in 
PKR deficient cells as compared with vector titers generated by naïve 293T cells. A similar 
increase in titers was observed for a conventional pTK945 vector. In theory these findings 
could be associated with low level of antisense mRNAs which could be transcribed from 
weak promoters embedded in the parental HIV-1 sequence and in the vector cassette and 
stabilized by the internal poly-A signal.74–77
Positioning the WPRE between the transgene of interest and the internal poly-A sequence 
significantly increased transgene expression from ECOO-comprising vectors without 
negatively affecting their titers. Unexpectedly, gene expression levels from ECOO-
comprising vectors were comparable or higher than the levels of expression from their 
conventional counterparts. Interestingly, the molecular mechanism involved in this 
phenomenon, which was more distinct in IDLV’s has not been elucidated in this study. 
However, it is possible that positioning the internal promoter in opposite orientation to the 
LTR distanced it from negative regulatory elements in the vector’s 5’ untranslated region. 
This phenomenon is a significant advantage of ECOO-comprising vectors. Furthermore, in 
contrast to conventional vectors, ECOO-comprising vectors should facilitate delivery of 
intron-containing genes, which significantly increase transgene expression.78–81 Overall, the 
data presented here outline an efficient methodology of producing high titer ECOO-
comprising vectors. The newly developed vector system is safer, more efficient at 
maintaining high levels of transgene expression and thus suites better than currently used 
lentiviral vectors for clinical trials.
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Figure 1. A vector cassette comprising a single-SIN LTR supports production of high titer 
lentiviral vectors.
(A) Depiction of the single-SIN LTR vector pTK485 showing the green fluorescence protein 
(GFP) marker gene under the control of the cytomegalovirus immediate early promoter 
(CMV) promoter. The pUC Ori bacterial origin of replication (Ori) and the ampicillin 
resistance gene (Amp) in pTK485 facilitate transfer of reverse transcribed episomal vector 
genomes from vector transduced cells to bacteria.11 Additional cis-acting elements include 
the Rev-response element (RRE), the central polypurine tract (cPPT), the woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) and the 3’ polypurine tract 
(PPT). Arrows indicate the direction of transcription. (B) Titers of VSV-G pseudotyped 
pTK485 particles generated by transient transfection in 293T cells using different packaging 
cassettes. Lane 1 packaging by a second-generation packaging cassette (Delta-NRF) deleted 
of the HIV-1 vpr, nef and vif genes. Lanes 2 and 3; packaging by a third generation-
packaging system comprising the gag-pol and rev gene expression cassettes (pMDL and 
pE2f-Rev, respectively) either without (lane 2) or with (lane 3) the HIV-1 Tat expression 
cassette (pSV-Tat). Transducing unit titers (TU/ml) were determined by scoring GFP 
positive cells following serial dilution on 293T cells at 72 hr post- transduction. Titers are 
represented as average of 3 independent experiment ± SD (Standard deviation).
Hu et al. Page 21
Gene Ther. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Knockdown of PKR expression in vector producing cells minimizes the negative effects 
of opposite orientation expression cassettes on lentiviral vector titers.
(A) Depiction of the SIN vectors pTK945 and pTK1906 carrying GFP expression cassettes 
in different orientations to the vector LTR’s. Arrows indicate the direction of transcription 
from the relevant internal promoters. (B) Bar-graph showing titers (TU/ml) of conventional 
and ECOO-comprising lentiviral vectors generated in naïve or PKR deficient cells. The 
conventional and ECOO-comprising vectors pTK945 and pTK1906 (respectively) were 
packaged by transient transfection in either naïve 293T cells (black bars) or following stable 
shRNA-mediated knockdown of PKR expression. Two different shRNA target clones (PKR 
sh1, PKR sh2) were employed to rule out shRNA off-target effects (PKR sh1-grey bar and 
PKR sh2-white bar). Vectors generated in 293T cells expressing β-globin-directed shRNA 
served as an additional negative control (diagonal lines). The vectors were generated in 3 
independent experiments (n=3). Vector titers (TU/ml) were measured by scoring GFP 
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expression following serial dilutions on 293T cells, and represented as average ± SD. (C) 
Concentration of physical vector particles in conditioned media was determined by p24gag 
ELISA. (D) Western blot analysis of PKR expression in the aforementioned four vector 
producing cell lines including naïve 293T cells (lane 1), cells expressing β-globin-directed 
shRNA (lane 2), cells expressing PKR-directed shRNA’s (PKR sh1-lane 3 and PKR sh2-
lane 4). Probing with β-actin-directed antibody served as loading control.
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Figure 3. Effects of internal polyadenylation (poly-A) sites and transcriptional activity of ECOO 
on vector titers.
(A) Depiction of lentiviral vectors carrying poly-A signal sequences and internal promoters 
in different orientations. Arrows indicate the direction of transcription. BGH: bovine growth 
hormone poly-A signal; SV40: Simian virus 40 poly-A signal; pbi: tetracycline regulated 
promoter. (B) Bar graphs describing titers (TU/ml) and (C) physical particle concentration of 
the lentiviral vectors: pTK1588, pTK1595, pTK1848, pTK1850. Vectors were produced by 
transient transfection in 3 different 293T cell lines: naïve cells (black bars), β-globin 
knocked-down cells (white bars) and PKR knocked-down cells (grey bars). Titers of the 
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conventional lentiviral vector pTK945 served as controls. Vectors were generated in 3 
independent experiments (n=3), and represented as average ± SD. Titers (TU/ml) were 
determined by scoring GFP positive cells following serial dilutions on 293T cells. 
Concentrations of physical vector particles were determined by p24gag ELISA. (D-E) Bar-
graphs describing vector titers and concentration of physical vector particles of lentiviral 
vectors carrying a tetracycline inducible promoter and either SV40 or BGH poly-A signals, 
including pTK1885, pTK1927, pTK1936, pTK1937 The vectors were generated in naïve 
(black and diagonal black lines bars) and PKR knockdown (grey and diagonal grey line 
bars) 293T cells, either in the presence (diagonal lines containing bars) or absence of the 
tetracycline-regulated trans-activator, tTA (black and grey bars). The conventional pTK945 
vector served as control. Vectors were generated in 3 independent experiments (n=3), and 
titer was represented as average ± SD. (D) Vector titers were determined by scoring GFP 
positive cells following serial dilutions on SODK0 cells, which constitutively express tTA. 
(E) Concentrations of physical vector particles were determined by p24gag ELISA.
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Figure 4. Improved vector design enhances vector titers.
(A) Depiction of lentiviral vectors comprising SV40 and BGH poly-A sites in various 
positions and orientations to the LTR’s. Arrows indicate either the direction of transcription 
from the internal CMV promoter or the orientation of the parental SV40 poly-A signal. 
BGH: bovine growth hormone poly-A signal; SV40: Simian virus 40 poly-A signal; pbi: 
tetracycline regulated-promoter. (B-C) Bar graphs describing vector titers and concentrations 
of physical vector particles. Lentiviral vectors pTK1886, pTK1906, pTK1907, pTK1908, 
pTK1909, and pTK1918 were generated by transient transfection in 3 different 293T-based 
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cell lines: naïve 293T cells (black bars), β-globin knockdown cells (white bars) and PKR1 
knockdown cells (grey bars). The conventional pTK945 vector served as a positive control. 
Vectors were generated in 3 independent experiments (n=3), and represented as average ± 
SD. (B) Vector titers (TU/ml) were determined at 72hr post-transduction by scoring GFP 
positive cells following serial dilutions on 293T cells. (C) Concentration of physical vector 
particles at p24gag level was measured by ELISA, and represented as average ± SD. (D) 
FACscan analysis of transgene (GFP) expression levels. Vector transduced 293T cells were 
harvested for FACscan analysis at 72 hours post-transduction. Mean fluorescence intensity 
(MFI) was quantified with the FlowJo software. Error bars represent the standard deviation 
of 3 independent measures. To minimize the effect of multi-vector transduction events on 
transgene expression analysis, target cells were transduced at a relatively low m.o.i (<0.1). 
Consequently, a percent of GFP-positive cells was lower than 17.2%. Representative flow 
histograms are shown in supplemental figure 2.
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Figure 5. Optimization of transgene expression from ECOO comprising vectors.
(A) Depiction of conventional and ECOO-comprising lentiviral vectors, pTK945, pTK1909, 
pTK1940 and pTK1954. Both vectors contain an internal WPRE (in opposite orientation to 
the LTR’s) between the transgene of interest (GFP) and the SV40 poly-A sequence. A 
second WPRE sequence in the same orientation to the LTR’s is positioned downstream to 
the 3’ LTR of pTK1954. Arrows indicate the direction of transcription from the internal 
CMV promoter or the orientation of the BGH poly-A and WPRE sequences positioned 
downstream to the 3’ LTR. (B-C) Bar graphs describing titers and concentrations of physical 
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vector particles. Lentiviral vectors pTK1940 and pTK1954 were generated by transient 
transfection in either naïve or PKR deficient (PKR1 cells) 293T cells. The conventional 
vector, pTK945 and the WPRE-lacking vector pTK1909 served as positive and negative 
controls, respectively. (B) Transducing vector titers (TU/ml) were determined by scoring 
GFP-positive cells following dilutions on 293T cells. (C) Concentration of physical vector 
particles in conditioned media at 72h post transfection were determined by p24gag ELISA. 
(D) Bar graph describing FACscan analysis of GFP expression levels as MFI in 293T cells at 
72hr post transduction with the ICLV’s pTK945, pTK1909, pTK1940 and pTK1954. The 
vectors were generated in PKR knockdown 293T cells. To minimize the effect of multi-
vector transduction events on transgene expression analysis, target cells were transduced at a 
relatively low m.o.i (<0.1). Consequently, percentages of GFP-positive cells were lower than 
19%. Representative flow histograms are shown in supplement figure 3. (E) Bar graph 
describing FACscan analysis of GFP expression levels as MFI in 293T cells at 72hr post 
transduction with the IDLV’s pTK945 and pTK1940. Naïve 293T served as a negative 
control. The vectors were generated in PKR knockdown 293T cells using an integrase 
deficient packaging cassette encoding the D64E integrase mutant. (F) Depiction of lentiviral 
vectors carrying firefly luciferase (Luc) expression cassettes driven by the liver specific, 
human alpha 1-antitrypsin (hAAT) promoter. Arrows indicate the direction of transcription 
from the internal hAAT promoter. (G) Bar graph describing efficiency of luciferase 
expression from the hAAT promoter at 72hr post transduction of HepG2 cells with 
conventional (pTK979) or ECOO-comprising vector pTK1956. Relative light units (RLU) 
were determined by luciferase assay and normalized to total protein concentration and vector 
copy number per cell (VCN) as determined by real time PCR. All data were represented as 
average ± SD of 3 independent experiments. P value (p=0.008) was determined by two tail 
student’s T test.
Hu et al. Page 29
Gene Ther. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Minimal mobilization of ECOO comprising SIN vectors.
Mobilization efficiency of the SIN ECOO-comprising vector pTK1940 and its conventional 
SIN and non-SIN counterparts vectors, pTK945 and pTK1087, respectively. (A) Depiction 
of conventional and ECOO-comprising non-SIN/SIN vectors (pTK1087/pTK945 and 
pTK1976/pTk1940, respectively). The non-SIN U3 in the 3’LTR’s are indicated. Arrows 
indicate the direction of transcription from the internal CMV promoter and the orientation of 
the WPRE, SV40 and BGH poly-A signals. (B) Lentiviral vector mobilization from 
episomal vector genomes at 72h post IDLV transduction of the tetracycline regulated stable 
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packaging cell line, SODk1, either in the presence of doxycycline or in the absence of 
doxycycline and the presence of sodium butyrate (uninduced or, induced respectively). 
Mobilized vector particles were employed on naïve 293T target cells. To dilute out carry 
over of non-mobilized IDLV’s, titers of mobilized ICLV’s (generated by the induced 
packaging cells) were determined following 5 passages of the above target cells in culture. 
Percentage of GFP-positive cells and the number target cells at the time of transduction were 
used to calculate vector titers. Black and white bars describe titers (TU/ml) of the above 
vectors mobilized from induced and uninduced SODk1 cells, respectively. Error bars 
represent standard deviation of 3 independent experiments. (C) Lentiviral vector 
mobilization from integrated vector genomes (pTK1087, pTK945 and pTK1940) in induced 
and uninduced SODk1 cells. Conditioned media were employed on 293T cells and vector 
titers were determined by scoring GFP positive cells following serial dilutions on 293T cells. 
Black and white bars describe titers (TU/ml) of the above vectors mobilized from induced 
and uninduced SODk1 cells, respectively. The results are average of three independent 
experiments. Asterisk indicates titers lower than detection level (<10TU/mL). (D) 
Normalized vector titers. To minimize bias of VCN in SODk1 on mobilized vector titers, 
calculated mobilization titers from ICLV-transduced SODk1 cells were normalized to VCN 
(vector producing SODk1 cells) as determined by real time PCR. Black and white bars 
describe normalized titers (TU/ml/copy) of the above vectors mobilized from induced and 
uninduced SODk1 cells, respectively. Titers were represented as average ± SD of 3 
independent experiments. (E-F) Characterizing the combined effect of SIN-LTRs and the 
orientation of lentiviral vector internal expression cassettes on mobilization of integrated 
lentiviral vectors. PKR-deficient 293T cells transduced with integrating ECOO-comprising 
non-SIN vector (pTK1976) and naïve 293T cells transduced with either, conventional non-
SIN and SIN vectors (pTK1087 and pTK945, respectively) or ECOO-comprising SIN and 
non-SIN vectors (pTK1976 and pTK1940, respectively) were analyzed for vector copy 
number by qPCR. The aforementioned vector-transduced 293T cell were transfected with a 
VSV-G envelope and the ΔNRF packaging cassettes. Mobilized vectors in conditioned 
media were collected at 72 hours post-transfection and tittered by scoring GFP expression 
following serial dilutions on 293T cells. (E) Bar graph describing titers of mobilized 
lentiviral vectors from integrated vector genomes in naïve (black bars) and PKR deficient 
(white bars) 293T cells. The results are average of three independent experiments. (F) Bar 
graph showing the above titers of mobilized vectors after normalization for VCN. The 
results are average of three independent experiments.
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Figure 7. ECOO-comprising lentiviral vectors for hepatic gene delivery and ex-vivo applications.
(A) In vivo imaging of lentiviral vectors-mediated hepatic luciferase expression. C57B6 
mice were intraperitoneally injected with 1.5×109 TU of the ECOO-comprising vector 
pTK1956 (5 mice) and its conventional counterpart pTK979 (4 mice). As shown in figure 5F 
both vectors carry the firefly luciferase under the control of a liver specific promoter hAAT. 
A single mouse injected with PBS served as a negative control. Luciferase expression was 
imaged by the IVIS Lumina optical system at week 2, 4, 6, and 8 post-injection. (B) Bar 
graph describing average levels of luciferase expression in mouse livers (photon/sec) at 
weeks 2, 4, 6 and 8 after intraperitoneal administration of lentiviral vectors pTK979 (black 
bars, average ± SD, n=4) and pTK1956 (grey bars, n=4), and 1 mouse injected with PBS 
(white bar, n=1). Mouse #4 injected with pTK1956 was excluded from this analysis. (C) 
Depiction of The CCL-βAS3-FB LV provirus. The corresponding viral vector was 
developed and described earlier by Romero et al at in the laboratory of Dr. Donald B. Kohn 
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at the University of California, Los Angeles (UCLA). The vector carries the HBBAS3 
expression cassette in opposite orientation to the LTR’s (depicted as HBBAS3-Exp). It 
comprises the β-globin promoter, exons and introns of the β-globin gene as well as its 3’ and 
5’ flanking regions including a poly-A site (between the globin coding sequence and the 
globin 3’ enhancer (Levasseur31 and Behringer 82 et al ). Also included is the β-globin mini-
LCR with the hypersensitive sites 2-4. The SIN U3 regions contain a 77 bp mini-insulator 
(depicted as FB). (D) Bar graph describing titers of VSV-G pseudotyped the ECOO-
comprising CCL-βAS3-FB and the conventional vector pTK945 generated in either naïve 
293T cells (black bars) or PKR knockdown 293T cells (Grey bars). Error bars represent 
standard deviation of 2 independent experiments.
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